MTND4LP2

Across TCGA pan-cancer cohorts, MTND4LP2 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated MTND4LP2 data layer.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MTND4LP2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTND4LP2 expression acts as an unfavorable survival marker, although some lineages such as LAML show a favorable association.

OV, STAD, and SKCM are the cancer types where MTND4LP2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Tertile	IV	0.082	0.798	<.001	108	view →
STAD	DFS	Tertile	All	0.501	0.768	<.001	63	view →
SKCM	DFS	Tertile	All	0.016	0.758	<.001	45	view →
LUAD	OS	Tertile	All	0.352	0.687	.005	36	view →
LUSC	OS	Tertile	II,III,IV	0.155	0.736	<.001	18	view →
UCEC	DFS	Tertile	III,IV	0.097	0.581	.044	18	view →
THCA	DFS	Tertile	All	0.184	0.814	.023	9	view →
BRCA	DFS	Tertile	All	0.769	0.903	.019	6	view →
LAML	DFS	Tertile	All	0.704	0.495	.044	4	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

MTND4LP2–OV (OS)

Open the OV breakdown →